Unveiling the Role of FAM72 Gene Family in Aggressive Hepatocellular Carcinoma
A groundbreaking bioinformatics study has shed light on the FAM72 gene family's potential as a powerful prognostic marker in hepatocellular carcinoma (HCC). The research reveals that high expression of FAM72 genes is strongly linked to more advanced disease stages and poorer survival outcomes.
The study, led by Kong and colleagues, analyzed the expression of FAM72A-D genes in liver cancer using The Cancer Genome Atlas (TCGA) and multiple external validation cohorts. All four FAM72 genes were found to be significantly upregulated in tumor tissue compared to normal liver tissue, and this upregulation was strongly associated with higher TNM stages, poorer histological grades, and worse overall prognosis. The diagnostic performance was impressive, with AUCs ranging from 0.88 to 0.94 for distinguishing between tumor and normal tissue.
A Unique Two-Gene Signature
The team's innovative approach involved developing a concise FAM72-based risk score. They discovered that mutations in FAM72A-D genes were relatively common (up to 17%) and were associated with reduced overall survival. Interestingly, a simple two-gene signature, combining FAM72A and FAM72D, demonstrated superior performance in stratifying patients into high- and low-risk groups across five independent cohorts. This two-gene signature outperformed ten previously published multi-gene HCC prognostic models, despite using fewer genes.
Single-cell RNA sequencing provided further insights, showing that FAM72B-D genes were enriched in proliferating T cells, while FAM72A was also present in myeloid and endothelial compartments. This suggests that FAM72 genes may play roles in both tumor cells and the immune microenvironment.
Implications for Immunotherapy
The study's findings have significant implications for immunotherapy strategies. High FAM72 expression and risk scores were strongly correlated with altered immune infiltration, including shifts in T-cell subsets and increased expression of immune checkpoints such as PDCD1, CD274, CTLA4, HAVCR2, ICOS, and TIGIT. These features could provide valuable insights for tailoring immunotherapy approaches.
Copy-number variation, rather than promoter methylation, was identified as the primary driver of FAM72 overexpression. Pathway analyses linked the high-risk FAM72 signature to cell-cycle control, DNA repair, and MYC-related programs, further supporting a role in tumor proliferation and genomic instability.
In conclusion, the FAM72A-D genes emerge as promising diagnostic and prognostic biomarkers in HCC. The streamlined FAM72 risk score has the potential to support risk stratification and guide future immunotherapy decisions, offering new avenues for improving patient outcomes.
